Genomic classifier (GC) tests do not appear to consistently influence risk classification or treatment decisions for patients with newly diagnosed prostate cancer considering first-line treatment, ...
Collaboration brings whole-exome based hereditary cancer insights to urologists and their patients by offering it alongside Veracyte's Decipher Prostate Test The partnership was also highlighted ...
Tests do not consistently influence risk classification or treatment decisions; authors call for well-designed trials on role of GC tests in newly diagnosed PCa. (HealthDay News) — For patients with ...
Hosted on MSN
A True Game-Changer in Prostate Cancer: A Simple Genomic Test Can Tell Us Who Needs Hormone Therapy And Who Doesn’t
If you or a loved one are navigating the journey of prostate cancer, you know that every decision weighs heavily. You’ve likely faced surgery or initial treatments, only to encounter the fear that ...
In the largest clinical genomic profiling study of non-Hispanic Black men with metastatic prostate cancer to date, researchers from Moffitt Cancer Center, University of Pennsylvania, University of ...
TAMPA, Fla. (Jan. 24, 2025) — A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris — can help ...
The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...
TAMPA, Fla. (Dec. 19, 2025) — A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback